Andera Partners' Olivier Litzka on Picking Biotech Winners Beyond the Hype Cycle

Olivier Litzka, a partner at Andera Partners (搜索)搜索该词条, a European life-science investor managing over $6 billion across funds, argues that successful biotech investing is less about picking perfect science and more about constructing a resilient portfolio, backing adaptable teams, and ruthlessly avoiding what he calls "failure for bad reasons" — the preventable operational, regulatory, and communication errors that derail companies before biology even gets a fair test. Speaking on The Business of Biotech with host Ben Comr, Litzka laid out a philosophy that cuts against a sector addicted to hype cycles, emphasizing discipline, honesty, and the long game.

A Portfolio of Stages, Not Just Science

Andera Partners (搜索)搜索该词条 operates a single-fund model that deliberately spans the entire company lifecycle. Litzka breaks down the allocation: roughly 20% goes to very early-stage and company-creation efforts, 50% targets the Series B to phase-one sweet spot, and 30% is reserved for more advanced companies, including those already listed in Europe and transferring to NASDAQ or late-stage medtech firms approaching commercialization.

This is not diversification for its own sake but a fundraising necessity. Institutional investors who back Andera's funds want to see returns within a reasonable horizon, and the later-stage positions provide liquidity events that keep capital flowing for the earlier, longer-gestation bets. Geographically, the firm is roughly two-thirds Europe and one-third US, with occasional forays into Israel and a growing interest in Chinese technologies via a dedicated colleague. Ticket sizes scale accordingly: a phase-three-ready company might warrant a €20–30 million investment, while an early-stage platform bet might start with just €2–3 million alongside a syndicate.

Litzka emphasizes that the firm is indication-agnostic and modality-agnostic, but deliberately avoids over-exposure to whatever is currently hyped. During the immuno-oncology boom of the early 2020s, Andera did not pile into combination checkpoint trials, recognizing that the sheer number of programs was unsustainable. Instead, the firm looks for genuine innovation in overlooked areas — a new mechanism in refractory hypertension (搜索)搜索该疾病, a novel approach in epilepsy (搜索)搜索该疾病 — where medical need remains high despite the existence of established drug classes.

Case Studies in Execution: Abivax and the Tupolis Pivot

Litzka's case studies illustrate the difference between betting on data and betting on people. The Abivax查看公司主页 story is a textbook example of a later-stage thesis executed flawlessly. The French company, listed on Euronext, had interesting phase-two data in ulcerative colitis (搜索)搜索该疾病 but had stagnated. The arrival of CEO Mark Daridel — a known quantity with whom Andera had done business — changed the calculus. The plan was to transfer the listing to NASDAQ and run a pivotal phase-three trial. Andera supported the move heavily, and the company delivered outstanding data, transforming from a company worth a few hundred million euros on Euronext into a multi-billion-dollar NASDAQ-listed entity.

The Tupolis (搜索)搜索该词条 story, by contrast, demonstrates the value of flexibility and honest reassessment. This Munich-based antibody-drug conjugate (ADC) company was an earlier-stage investment made around 2022. The team was extremely smart and had built a broad network, but the clinical program was not exciting. Rather than forcing a bad program forward, the board — including Andera — made the difficult call to pivot back to preclinical development and focus on the company's linker technology, which proved highly versatile. The company raised enormous sums, generated compelling initial clinical data, and was ultimately acquired by Gilead查看公司主页 in 2026, with the Munich site retained.

Litzka's framing is instructive: the job of a board is to help a company "fail for the good reasons" — scientific failure that is honest and inevitable — while preventing "failure for the bad reasons," which are entirely avoidable. "Our job as I understand it is interacting with companies and the people, helping where we can, providing the money with others," he said. "But helping where we can that the company fails for the good reasons if it has to fail. And avoid failing for the bad reasons."

The "Bad Reasons" for Failure

Litzka is specific about the operational failure modes that sink biotech companies, and they are rarely the science. The list includes investor pressure leading to withheld tranches despite milestones being met, management sugar-coating problems instead of surfacing them, CDMO partners failing to deliver on time, and — for listed companies — poor communication to the market. The common thread is a culture of honesty and directness that must be established from day one.

The antidote, in Litzka's view, is a board and management team that talk about "the real stuff." He warns that hand-waving — "it will be okay" — is the most dangerous phrase in the industry. "Talking, talking about the real stuff, right? And then addressing it, and hand-waving is always problem, right? It will be okay. It will be okay. That's dangerous," he said. The board's role is to identify risk zones, discuss them openly, and concentrate on improving the two or three most critical items at each meeting.

Europe's Broken Ecosystem and the Three-Pillar Fix

Andera's participation in the European Life Sciences Coalition — a growing group of major European VCs, law firms, and biotech organizations — reflects a recognition that individual company success is constrained by systemic weaknesses. Litzka articulates the coalition's three-pillar agenda: regulatory pragmatism (making Europe's overly complicated and slow regulations practical, easier, and faster without lowering quality standards); institutional capital (attracting European pension funds and insurance companies, which invest far less in venture capital and life sciences than their US counterparts); and the creation of a NASDAQ-equivalent public market in Europe.

The Euronext story is a cautionary tale. In 2014–15, there was genuine hope that Euronext — the assembly of the Paris, Brussels, and Amsterdam exchanges — could become Europe's growth market. It succeeded in raising initial capital but failed as a venue for companies to grow and raise follow-on funding, with insufficient analyst coverage, too few European public investors, and an over-reliance on retail investors. The result: companies like Abivax查看公司主页 and Inventiva查看公司主页, both Andera portfolio companies, switched to NASDAQ listings. Litzka's diagnosis is blunt — the wealth generation from European innovation is happening in the US because that is where the capital and the follow-on support exist.

AI as a Tool, Not a Silver Bullet

Litzka's assessment of AI's role in biotech is measured and pragmatic. His position: AI is now table stakes — every credible company must be able to articulate where and how it applies AI across its development pipeline. The clearest near-term win is in patient population preselection, where AI has already demonstrated an ability to improve phase-one success rates. Litzka also cites compound selection, testing optimization, and preclinical development as areas where AI delivers measurable productivity gains.

The critical limitation is that AI is only as good as the knowledge base it is trained on, and biology is fundamentally more complex than current knowledge captures. "If AI would solve everything, you know, we didn't need, we wouldn't need clinical trials. We do need clinical trials. Why? Because the biochemistry and the biology is more complicated than we think, because it's only based on the current knowledge and this is not perfect," he said.

The China Question: Competition and Partnership

Litzka takes the Chinese biotech threat seriously, and he is explicit that European and American companies should too. The ADC space is his primary example: the sheer volume and diversity of payloads, linkers, and bispecific combinations emerging from China is staggering. The Chinese machinery for generating innovation is real, and it is fast.

But the response is not protectionism — it is a combination of vigilance and partnership. Andera actively licenses Chinese candidates into European and US companies, builds companies around them, and even anticipates Chinese acquirers for European assets. The competitive response, Litzka argues, must be a commitment to outstanding science and scientific excellence — the one area where Europe and the US can still maintain an edge. The FDA's recent pilots to accelerate the path to NDA, which Litzka notes have been partly motivated by Chinese competition, are a recognition that regulatory agility is a competitive weapon.